Inscripta has presented its scalable platform for benchtop digital CRISPR engineering, described as world first, at the 2019 Synthetic Biology: Engineering, Evolution & Design (SEED) conference. The technology, “CRISPR-enabled trackable genome engineering” or CREATE, is meant to remove certain limitations of CRISPR to allow for more wide-reaching research in the future.
The last common male ancestor of all humans is far older than previously thought, scientists have found. When the family of Albert Perry, an African-American living in South Carolina, submitted his DNA to commercial genealogy company Family Tree DNA, it was discovered that his Y chromosome was so distinct that his male lineage likely separated from all others around 338,000 years ago.
The amount of data captured by pharma companies today is fast outpacing best use for it. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or missing a potential opportunity that their rivals seize. Stemming from Front Line Genomics’ […]
From 1 July, international scientists looking to use Chinese genetic material and data must have at least on Chinese collaborator working with them, according to new regulations. This follows a trend as individuals and organisations realise the value of their genetic data.
Consumer genomics company Ancestry has launched the new upgrade to its AncestryDNA experience, Ancestry Communities. Contrary to many commercial DNA sites, Communities promises to specify UK users’ genetic ancestry to a county level.
The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.
BIO 2019 – An Interview with Irene Rombel, Senior Director and Head of Strategic Analysis at Janssen
With the recent conclusion of the Biotechnology Innovation Organization’s BIO 2019 event, we thought we’d talk to some of the fascinating individuals who were present to showcase their innovative ideas or technologies. Irene Rombel, Senior Director, Head of Strategic Analysis – External Innovation, Discovery, Product Development & Supply, at Janssen Research & Development, spoke at BIO 2019 about gene therapy and the next generation of biotherapeutics. We spoke to her about her thoughts on the gene therapy field, and the future for companies in that space.
eGenesis has announced that it is now testing pig organs on primates to see if they safe for human use. If successful, this practice could solve the current shortage of human organs for transplantation. The company has declared that the pig organs are the most highly engineered ever created by surgeons.
Russian biologist Denis Rebrikov has announced his intentions to produce further gene-edited babies, ignoring the scientific consensus that this should not be done until an ethical framework is constructed to regulate the science involved. Rebrikov’s plans could occur before the end of the year if he receives approval in time.
As part of the Next Generation Children project at Addenbrooke’s Hospital and Cambridge University, all seriously ill children in England with unexplained disorders will be able to have their genomes analysed from 2020. The project should mean quicker diagnoses for families in the future.
Dr. Eric Kmiec, Director of the Gene Editing Institute at Christiana Care Health System, spoke at BIO 2019 about meeting unmet medical needs with gene editing. We spoke to him about his work at Christiana Care Health System and CRISPR’s role in promoting better social equality in life science.
Researchers have genetically modified stem cells inside the bodies of mice for the first time, in a study that could lead eventually to new potential for stem cell therapies. The study also shows potential for studying genetically-edited stem cells within the body, rather than in the lab.
He Jiankui, the Chinese scientist who created the first gene-edited twin children last year, could have unknowingly shortened their lives by more than 1.9 years. A study into the DNA and death records of 400,000 volunteers in the UK Biobank found the genetic mutations to gene CCR5 were “of quite strong effect.”